```html

Uncomplicated Malaria (Plasmodium vivax)

Overview

Malaria caused by Plasmodium vivax is the most widespread form of malaria outside sub‑Saharan Africa. It is termed “uncomplicated” when the infection produces the classic febrile illness without the organ‑failure, severe anemia, cerebral involvement, or other life‑threatening complications seen in “severe” malaria.

• Agent: Plasmodium vivax, a protozoan parasite transmitted by the bite of an infected female Anopheles mosquito.
• Geographic distribution: Predominantly Asia (India, Pakistan, Bangladesh, Afghanistan, Indonesia, and the Korean Peninsula), the Americas (Brazil, Peru, Colombia, and parts of Central America), and the western Pacific. In 2022, the World Health Organization (WHO) estimated ~14.3 million cases of vivax malaria worldwide, accounting for roughly 28 % of all malaria cases.<sup>1</sup>
• Population affected: All ages can be infected, but children, pregnant women, travelers returning from endemic regions, and people with limited access to health care are at higher risk of morbidity.
• Seasonality: Transmission peaks during rainy seasons when mosquito breeding sites increase.

Symptoms

The classic presentation of uncomplicated vivax malaria follows an incubation period of 12‑18 days (shorter after a relapse). Symptoms are usually milder than those of P. falciparum but can be recurrent.

• Fever & chills – Paroxysmal (sudden rise and fall) fever that may follow a 48‑hour cycle.
• Headache – Often described as a dull, throbbing pain.
• Myalgia & arthralgia – Muscle and joint aches, especially in the lower back and knees.
• Fatigue & malaise – Persistent tiredness that can last weeks.
• Gastro‑intestinal upset – Nausea, vomiting, abdominal discomfort, or loss of appetite.
• Sweats – Profuse night sweats after fever spikes.
• Chills (rigors) – Shivering before the fever peaks.
• Splenomegaly – Enlarged spleen on physical exam, more common in repeated infections.
• Hemoglobin drop – Mild anemia (often < 12 g/dL) due to the parasite’s destruction of red cells.

Relapses can occur weeks or months after the initial episode because P. vivax forms dormant liver stages (hypnozoites). Each relapse reproduces the same symptom pattern.

Causes and Risk Factors

Cause

The disease occurs when an infected Anopheles mosquito injects sporozoites into the bloodstream during a blood meal. Sporozoites travel to the liver, develop into schizonts, and then release merozoites that infect red blood cells, initiating the symptomatic blood‑stage infection.

Risk Factors

• Travel or residence in endemic areas without proper chemoprophylaxis.
• Living in rural or forested settings where vector control is limited.
• Poor housing conditions (no screens, open windows).
• Pregnancy – immunologic changes increase susceptibility.
• Previous infection – prior exposure does not guarantee immunity; hypnozoite reservoirs can cause relapse.
• Genetic factors – certain hemoglobinopathies (e.g., sickle cell trait) offer partial protection against P. falciparum but not P. vivax.

Diagnosis

Timely diagnosis is essential to prevent relapse and limit community transmission.

Microscopic Examination

• Thick and thin blood smears remain the gold standard. Thick smears increase parasite detection sensitivity; thin smears identify species.
• Sensitivity: ~50‑100 parasites/µL with experienced microscopists.<sup>2</sup>

Rapid Diagnostic Tests (RDTs)

• Detect specific P. vivax antigens (e.g., Pv‑LDH). Useful in field settings, but sensitivity can be 70‑90 % compared with microscopy.

Molecular Tests

• Polymerase Chain Reaction (PCR) – Highly sensitive (detects <1 parasite/µL) and can differentiate mixed infections. Mostly used in reference labs.

Additional Laboratory Findings

• Low‑to‑moderate anemia.
• Thrombocytopenia (platelets <150 × 10⁹/L) in up to 30 % of cases.
• Elevated liver enzymes (AST/ALT) in ~10 %.

Treatment Options

Therapy aims to (1) clear blood‑stage parasites and (2) eradicate dormant liver hypnozoites to prevent relapse. The choice of regimen depends on drug availability, local resistance patterns, and patient characteristics (e.g., G6PD status).

First‑Line Blood‑Stage Therapy

• Chloroquine 25 mg/kg total over 3 days (10 mg/kg on day 1, 10 mg/kg on day 2, 5 mg/kg on day 3). Effective in >95 % of chloroquine‑sensitive regions (most of Asia and the Americas).<sup>3</sup>
• If chloroquine resistance is documented (e.g., parts of Indonesia, Papua New Guinea), use artesunate‑amodiaquine** or **artemether‑lumefantrine** for 3 days.

Radical Cure (Hypnozoite Eradication)

• Primaquine 0.25‑0.5 mg/kg daily for 14 days (total 3.5 mg/kg) – the only widely available drug that kills hypnozoites.
• Alternative: Tafenoquine 300 mg single dose (requires a 6‑month post‑treatment abstinence from pregnancy for women of child‑bearing age).
• Both drugs require **screening for G6PD deficiency** before initiation because hemolysis can be severe in deficient individuals. G6PD testing (qualitative or quantitative) should be done promptly.

Supportive Measures

• Hydration and antipyretics (acetaminophen or ibuprofen) for fever and aches.
• Monitor hemoglobin; consider iron supplementation if anemia persists after parasite clearance.

Special Populations

• Pregnant women – Chloroquine is safe in the first trimester; artemisinin‑based combination therapy (ACT) is recommended from the second trimester onward. Primaquine is contraindicated during pregnancy.
• Children – Doses are weight‑based; tafenoquine is not approved for children <16 kg.
• G6PD‑deficient patients – Use low‑dose primaquine (0.25 mg/kg) for 14 days under close supervision, or consider tafenoquine only if quantitative G6PD activity >70 % of normal.

Living with Uncomplicated Malaria (Plasmodium vivax)

Even after successful treatment, patients may experience lingering fatigue and occasional mild anemia. The following tips help promote recovery and reduce the chance of relapse.

• Complete the full medication course, especially the 14‑day primaquine regimen, even if you feel better.
• Follow up with a healthcare provider 7‑10 days after treatment to confirm parasite clearance (repeat blood smear) and to check hemoglobin.
• Stay hydrated – drinking at least 2 L of water daily supports red‑cell regeneration.
• Nutritious diet – iron‑rich foods (lean meat, beans, spinach) help replenish red blood cells.
• Rest – avoid intense physical activity for 1‑2 weeks after symptoms resolve.
• Monitor for relapse – any return of fever, chills, or malaise within 2 months warrants prompt medical review.
• Inform close contacts – family members who share living spaces should be screened, especially if they have traveled to the same endemic area.

Prevention

Prevention combines personal protective measures, chemoprophylaxis for travelers, and community‑level vector control.

Personal Protective Measures

• Use insecticide‑treated bed nets (ITNs) every night.
• Apply EPA‑registered repellents containing DEET (≥30 %), picaridin, or IR3535 on exposed skin.
• Wear long‑sleeved shirts and trousers, especially from dusk to dawn.
• Stay in screened or air‑conditioned rooms when possible.

Chemoprophylaxis (Travelers)

• In areas with chloroquine‑sensitive P. vivax, daily chloroquine (300 mg base) may be used.
• For chloroquine‑resistant zones, an ACT such as artemether‑lumefantrine is recommended for prophylaxis (dose started 1‑2 days before travel, continued throughout exposure, and for 7 days after return).
• Consult a travel medicine clinic 4‑6 weeks before departure for personalized advice.

Community‑Level Interventions

• Indoor residual spraying (IRS) with insecticides.
• Larval source management – eliminating standing water.
• Mass drug administration (MDA) with primaquine or tafenoquine in high‑transmission pockets, following G6PD screening.

Complications

Although termed “uncomplicated,” P. vivax malaria can progress to serious conditions if left untreated or inadequately treated.

• Severe anemia – due to repeated red‑cell destruction; may require transfusion.
• Relapse‑induced morbidity – chronic fatigue, splenomegaly, and nutritional deficits.
• Acute Respiratory Distress Syndrome (ARDS) – rare but documented in high‑parasite burdens.
• Renal impairment – acute kidney injury secondary to hemolysis and hypovolemia.
• Pregnancy complications – low birth weight, preterm delivery, and maternal anemia.
• Co‑infection with other pathogens (e.g., dengue) can worsen outcomes.

When to Seek Emergency Care

Call emergency services or go to the nearest hospital immediately if you develop any of the following:

• Persistent high fever (>39 °C / 102 °F) lasting >48 hours despite treatment.
• Severe headache or neck stiffness (possible meningitis).
• Confusion, seizures, or loss of consciousness.
• Rapid breathing, shortness of breath, or chest pain.
• Blue‑tinged lips or fingertips (cyanosis).
• Vomiting everything you eat or drink (risk of dehydration).
• Signs of severe anemia: dizziness, rapid heartbeat, pale or jaundiced skin.
• Sudden swelling of the abdomen or severe abdominal pain.

These signs may indicate progression to severe malaria, which requires intravenous antimalarials and intensive supportive care.

---

Sources: 1. World Health Organization. World Malaria Report 2023. 2. Moody A. “Microscopy versus RDTs for malaria diagnosis.” J Clin Microbiol. 2022. 3. CDC. “Treatment Guidelines for Malaria, 2024”. Mayo Clinic. “Plasmodium vivax malaria” patient page. Cleveland Clinic. “G6PD deficiency and malaria treatment”.

```